COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #214 of 260
12/14 Late treatment study
Tan et al., Virus Research, doi:10.1016/j.virusres.2020.198262 (Peer Reviewed)
A retrospective comparison of drugs against COVID-19
Source   PDF   Share   Tweet
Retrospective 333 patients in China, with only 8 HCQ patients, showing shorter duration of hospitalization with HCQ.

Tan et al., 12/14/2020, retrospective, China, Asia, peer-reviewed, 7 authors.
hospitalization time, 35.2% lower, relative time 0.65, p = 0.04, treatment 8, control 277.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 260 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit